Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GABRP | O00591 | 3/20 | 0.44 |
| ▸ | GABRD | O14764 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.44 |
| ▸ | GABRE | P78334 | 3/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21441709 | 0.82 | ABL1 (0.35) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL612856 | 0.81 | KDM4E (0.48) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL9508567 | 0.79 | KDM4E (0.47) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL30668508 | 0.79 | HCAR2 (0.48) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL6052889 | 0.79 | HCAR2 (0.48) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL38664726 | 0.79 | CA12 (0.50) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL4701685 | 0.78 | CA12 (0.45) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL473906 | 0.78 | KDM4E (0.46) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL2324851 | 0.78 | KMT2A (0.55) | KMT2AKDM4EGABRPGABRDGABRA1 | |
| SCHEMBL6032875 | 0.78 | AGBL2 (0.47) | KMT2AKDM4EGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117083263-A | Hydrazide compound, curable resin composition, sealant for liquid crystal display element, and liquid crystal display element | 积水化学工业株式会社 | 2023-11-17 | — | — | CN | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-10138207-B2 | Benzomorphan analogs and the use thereof | PURDUE PHARMA, L.P. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-3333156-A2 | BENZOMORPHAN ANALOGS AND THE USE THEREOF | Purdue Pharma L.P. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2917182-B1 | BENZOMORPHAN ANALOGS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| EP-3189041-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | Ctxt Pty Ltd (AU) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-0854721-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6127371-A | FOR TREATMENT OR PREVENTION OF CARDIOVASCULAR AND RENAL DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5985886-A | USEFUL IN THE TREATMENT OF A VARIETY OF CARDIOVASCULAR AND RENAL DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| US-5942516-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1999-08-24 | — | — | US | disclosed |
| EP-0854721-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0854721-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997004781-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | KMT2A 1400/4885KDM4E 1830/4885GABRP 1387/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | KMT2A 1162/4885KDM4E 1355/4885GABRP 1111/4885 |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | KMT2A 38/4885KDM4E 61/4885GABRP 4110/4885 |
| US-10138207-B2 | Benzomorphan analogs and the use thereof | OPRL1, OPRD1, OPRM1 | KMT2A 3150/4885KDM4E 3004/4885GABRP 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.